The heart metabolism: pathophysiological aspects in ischaemia and heart failure.

Research output: Contribution to journalReview article

Standard

The heart metabolism: pathophysiological aspects in ischaemia and heart failure. / Abozguia, K; Shivu, Ganesh; Ahmed, Ibrar; Phan, Thanh; Frenneaux, Michael.

In: Current pharmaceutical design, Vol. 15, No. 8, 01.01.2009, p. 827-35.

Research output: Contribution to journalReview article

Harvard

APA

Vancouver

Author

Bibtex

@article{cf7152ecdcb04a30a02f66f34e5f91ea,
title = "The heart metabolism: pathophysiological aspects in ischaemia and heart failure.",
abstract = "The morbidity and mortality of coronary heart disease and of heart failure remain unacceptably high despite major advances in their management. The main focus of treatment has been revascularisation for ischaemic heart disease and neuro-humoral modification for heart failure. There is an urgent need for new modalities of treatment to improve mortality and morbidity. Recently, there has been a great deal of interest in the role of disturbances in cardiac energetics and myocardial metabolism in the pathophysiology of both ischaemic heart disease and heart failure and of therapeutic potential of metabolic modulation. The myocardium is a metabolic omnivore, but mainly uses fatty acids and glucose for generation of Adenosine-5'-triphosphate (ATP). This review focuses on the key changes that occur to the metabolism of the heart in ischaemia and in heart failure and its effects on cardiac energetics.",
keywords = "ischaemia, Heart failure, myocardial metabolism, pathophysiology",
author = "K Abozguia and Ganesh Shivu and Ibrar Ahmed and Thanh Phan and Michael Frenneaux",
year = "2009",
month = jan,
day = "1",
doi = "10.2174/138161209787582101",
language = "English",
volume = "15",
pages = "827--35",
journal = "Current pharmaceutical design",
issn = "1381-6128",
publisher = "Bentham Science Publishers",
number = "8",

}

RIS

TY - JOUR

T1 - The heart metabolism: pathophysiological aspects in ischaemia and heart failure.

AU - Abozguia, K

AU - Shivu, Ganesh

AU - Ahmed, Ibrar

AU - Phan, Thanh

AU - Frenneaux, Michael

PY - 2009/1/1

Y1 - 2009/1/1

N2 - The morbidity and mortality of coronary heart disease and of heart failure remain unacceptably high despite major advances in their management. The main focus of treatment has been revascularisation for ischaemic heart disease and neuro-humoral modification for heart failure. There is an urgent need for new modalities of treatment to improve mortality and morbidity. Recently, there has been a great deal of interest in the role of disturbances in cardiac energetics and myocardial metabolism in the pathophysiology of both ischaemic heart disease and heart failure and of therapeutic potential of metabolic modulation. The myocardium is a metabolic omnivore, but mainly uses fatty acids and glucose for generation of Adenosine-5'-triphosphate (ATP). This review focuses on the key changes that occur to the metabolism of the heart in ischaemia and in heart failure and its effects on cardiac energetics.

AB - The morbidity and mortality of coronary heart disease and of heart failure remain unacceptably high despite major advances in their management. The main focus of treatment has been revascularisation for ischaemic heart disease and neuro-humoral modification for heart failure. There is an urgent need for new modalities of treatment to improve mortality and morbidity. Recently, there has been a great deal of interest in the role of disturbances in cardiac energetics and myocardial metabolism in the pathophysiology of both ischaemic heart disease and heart failure and of therapeutic potential of metabolic modulation. The myocardium is a metabolic omnivore, but mainly uses fatty acids and glucose for generation of Adenosine-5'-triphosphate (ATP). This review focuses on the key changes that occur to the metabolism of the heart in ischaemia and in heart failure and its effects on cardiac energetics.

KW - ischaemia

KW - Heart failure

KW - myocardial metabolism

KW - pathophysiology

U2 - 10.2174/138161209787582101

DO - 10.2174/138161209787582101

M3 - Review article

C2 - 19275646

VL - 15

SP - 827

EP - 835

JO - Current pharmaceutical design

JF - Current pharmaceutical design

SN - 1381-6128

IS - 8

ER -